Vasculoprotective effects of oestrogens.
1. The rationale for preclinical research on the atheroprotective effect of oestrogens is based on the epidemiological evidence that women are protected against the clinical complications of atherosclerosis until menopause. However, this protection, probably due to sex hormones, is progressively lost within the years following menopause. 2. In addition, numerous studies have clearly demonstrated the atheroprotective effect of oestrogens in all animal models. 3. In the present paper, we first summarize our understanding of the pathophysiology of atherosclerosis. We then focus on the recognized target of oestradiol (E2) in the vessel wall: the classical target, namely the endothelium, and a recently characterized target, namely cells of the inflammatory-immune system. Finally, we discuss how unknown mechanisms in atherosclerosis could be responsible for the absence of effect of hormone-replacement therapy in the Heart and Estrogen/ progestin Replacement Study (HERS).
Arnal
J F
JF
INSERM U397 et Laboratoire de Physiologie, CHU Rangueil, Toulouse, France. arnal@rangueil.inserm.fr
Bayard
F
F
D001161:Arteriosclerosis / Q000188:drug therapy / Q000503:physiopathology*; D004730:Endothelium, Vascular / Q000187:drug effects* / Q000502:physiology; D015914:Estrogen Replacement Therapy; D004967:Estrogens / Q000494:pharmacology* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D017698:Postmenopause / Q000502:physiology
D004967:Estrogens